TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03695523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY (PhysicaL ActivitY) Policy Intervention
Description: An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
Study: NCT01551589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Elective Nodal Irradiation (ENI)
Description: The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
Study: NCT00809432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask (Dust Respirator)
Description: Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Face mask
Description: Subjects will not wear a face mask to reduce their personal exposure to air pollution
Study: NCT01440049

Intervention type: OTHER
Intervention: Prospective Observational
Description: this is an observational study non interventional
Study: NCT04547803

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Visit
Description: 15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
Study: NCT01725867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT program
Description: manual myofascial release for craniomandibular system for 30\~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oral appliance
Description: custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
Study: NCT03844412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: The comparison treatment will be an identical-appearing placebo pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: The comparison treatment will be an identical-appearing placebo pill
Study: NCT00833729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: 50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
Study: NCT04014192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Treated with dapagliflozin 10mg/d for one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Treated with empagliflozin 10mg/d for one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Treated with canagliflozin 100mg/d for one week.
Study: NCT01468961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: 10 weeks of internet-based CBT with online therapist contact
Study: NCT02958072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LeucoPatch
Description: LeucoPatch is an fully autologous growth factor-containing dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LeucoPatch
Description: LeucoPatch is an fully autologous growth factor-containing dressing
Study: NCT03186378

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VP-102 with applicator
Description: Subjects will receive treatment to their molluscum contagiosum with VP-102.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VP-102 with applicator
Description: Subjects will receive treatment to their molluscum contagiosum with VP-102.
Study: NCT03931811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short wave diathermy
Description: SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Prolotherapy
Description: Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
Study: NCT03191305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
Study: NCT02375763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software instruction
Study: NCT03931811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
Study: NCT03191305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivoroxaban
Description: The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
Study: NCT00684554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Dose is determined according to the participants' individual need.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Dose is determined according to the participants' individual need.
Study: NCT04502186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raising Our Spirits Together
Description: Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Control Condition
Description: The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
Study: NCT04221048

Intervention type: OTHER
Intervention: Retrospective observational
Description: Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
Study: NCT02375763

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Software instruction
Study: NCT04302090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regulated expiratory method
Description: This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
Study: NCT02940223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl Icosapentate
Description: Given by mouth 2 gm orally daily plus physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete resistance exercises and undergo walking program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete resistance exercises and undergo walking program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Meet with exercise specialist and complete stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00717418

Intervention type: DRUG
Intervention: cyclosporine ophthalmic emulsion 0.05%, artificial tears
Description: one drop, twice a day in each eye
Study: NCT02021500

Intervention type: DRUG
Intervention: ABI-007
Description: No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
Study: NCT00205504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri Cyclen
Description: Ortho Tri Cyclen, one tablet daily, for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri Cyclen
Description: Ortho Tri Cyclen, one tablet daily, for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri Cyclen
Description: Ortho Tri Cyclen, one tablet daily, for 6 cycles
Study: NCT04635696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Description: Pressurized vapocoolant developed for acute, mild pain relief.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tissue culture grade water
Description: Pressurized water mist
Study: NCT00269386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
Study: NCT04383977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Etoposide capsule
Description: Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
Study: NCT00876174

Intervention type: PROCEDURE
Intervention: Blood sampling of peripheral blood mononuclear cells
Description: Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy

Intervention type: PROCEDURE
Intervention: Blood draw, 20ml peripheral blood mononuclear cells
Description: One time blood draw of 20 ml
Study: NCT02013193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ranger DCB
Description: After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated PTA balloon
Description: The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
Study: NCT02025972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood therapy
Study: NCT04151381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aminophylline
Description: the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
Study: NCT04018014

Intervention type: OTHER
Intervention: CT angiography
Description: CT angiography in detection of pulmonary embolism

Intervention type: OTHER
Intervention: CT angiography
Description: CT angiography in detection of pulmonary embolism
Study: NCT02940223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02058355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consequences List Feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consequences List Feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Study: NCT00759512

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Touch
Study: NCT04316572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental health specialist video consultation
Description: The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner
Study: NCT01207739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin and hydroxychloroquine
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
Study: NCT02940223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04111549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based telehealth GOALS
Description: Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person GOALS
Description: Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
Study: NCT03825666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ProvideXtra® Fresenius Kabi
Description: Improving wellbeeing
Study: NCT03622515

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anesthesia level and cerebral perfusion pressure
Description: Anesthetic dose and blood pressure
Study: NCT00413166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-Trans Retinoic Acid (ATRA)
Description: Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (ATO)
Description: Induction: 0.15 mg/kg daily IV beginning day 1
Study: NCT01207739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
Study: NCT00985881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom prosthetic socket with mechanical vibrators (stochastic resonance)
Description: Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
Study: NCT04223687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage Warning Label
Description: Labels with a pictorial warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research.

Intervention type: OTHER
Group type: OTHER
Intervention: Neutral label
Description: Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
Study: NCT02277366

Intervention type: PROCEDURE
Intervention: Fluorescence Bronchoscopy/Narrow Band Bronchoscopy
Description: Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
Study: NCT00879619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study: NCT00985881

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional prosthetic socket (current clinical practice)
Description: No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
Study: NCT05474716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% ophthalmic solution
Description: Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
Study: NCT03008980

Intervention type: OTHER
Intervention: Diagnostic Test

Intervention type: OTHER
Intervention: Diagnostic Test

Intervention type: OTHER
Intervention: Diagnostic Test

Intervention type: OTHER
Intervention: Diagnostic Test

Intervention type: OTHER
Intervention: Diagnostic Test

Intervention type: OTHER
Intervention: Diagnostic Test